Raphael Pharmaceutical (RAPH) Profit After Tax Growth (1y) (2021 - 2024)
Raphael Pharmaceutical (RAPH) Profit After Tax Growth (1y) (2021 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.33 Bn | 87.46 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | 67.73% |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn | -0.17% |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | -388.33% |
| 5 | United Therapeutics | 23.12 Bn | 20.96 Bn | 648.10 Mn | -14.68% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn | 105.80% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 1,682.88% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | -14.93% |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -423.77% |
| Sep 30, 2024 | 55.03% |
| Jun 30, 2024 | 40.53% |
| Mar 31, 2024 | -108.33% |
| Dec 31, 2023 | 111.06% |
| Sep 30, 2023 | 49.76% |
| Jun 30, 2023 | 33.49% |
| Mar 31, 2023 | -42.70% |
| Dec 31, 2022 | -94.53% |
| Sep 30, 2022 | -246.88% |
| Jun 30, 2022 | -62.02% |
| Mar 31, 2022 | 27.45% |
| Dec 31, 2021 | -146.52% |